Drugs / HS-10504
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07685041 | Jun → Nov 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06461156 | Jul 2025 → Dec 2026 expected | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414953 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor targeting EGFR C797S mutation” NCT06461156 ↗ |
| Route | Oral | “administered orally once daily” NCT06461156 ↗ |
| Target | EGFR | “targeting EGFR C797S mutation” NCT06461156 ↗ |